Huadong Medicine To Acquire Stake In Two Pharmaceutical Firms
This article was originally published in PharmAsia News
Executive Summary
Huadong Medicine has proposed allocating 98 million yuan ($13.9 million) to purchase 78.87 percent of Xi'an Bodyguard Pharmaceutical's stake and 65 percent of Shaanxi Jiuzhou Pharmaceutical's shares. According to Huadong Medicine officials, the two candidate companies possess the capability to produce pharmaceutical raw materials and preparations, as well as expand manufacturing to effectively alleviate Huadong Medicine's tight production situation. Xi'an Bodyguard's antiprotozoal product ornidazole enjoys major market share in China, while Jiuzhou Pharmaceutical has obtained approval to make strictly controlled narcotic drugs that enjoy monopoly in the country. (Click here for more - Chinese Language)
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.